Reportlinker Adds Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

News provided by

Reportlinker

Aug 31, 2010, 12:45 ET

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

http://www.reportlinker.com/p0286300/Epigenetics-Therapeutics-to-2017-–-High-Market-Potential-for-Epigenetics-Drugs-in-Acute-Myeloid-Leukemia-Multiple-Myeloma-and-Cutaneous-T-Cell-Lymphoma.html

Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

Summary

GBI Research's report, "Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma", provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the technology that shape the industry dynamics for the key geographies: the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Further, the report provides competitive benchmarking for the leading companies and analyzes the licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The Scope of this report includes:

- Annualized market data from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading technology in this space

- Market characterization

- Key drivers and barriers that have a significant impact on the market.

- Competitive benchmarking of leading companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 GBI Research Report Guidance 7

3 Market Characterization: Global Epigenetics Market 8

3.1 Disease Overview 8

3.1.1 Myelodysplastic Syndrome 8

3.1.2 Cutaneous T-cell Lymphoma 8

3.2 Epigenetic Drugs 9

3.3 The US 11

3.4 Top Five European Markets 12

3.5 Japan 14

4 In-Depth Analysis 16

4.1 Introduction 16

4.2 Vidaza (Azacitidine) 16

4.2.1 Indication 16

4.2.2 Mechanism of Action 16

4.2.3 Revenue Forecast 16

4.2.4 Key Takeaway 23

4.2.5 Market Potential 23

4.2.6 Pipeline Analysis 29

4.2.7 Drug Profile 32

4.3 Dacogen (Decitabine) 33

4.3.1 Indication 33

4.3.2 Mechanism of action 33

4.3.3 Revenue Forecast 34

4.3.4 Key Takeaway 39

4.3.5 Market Potential 39

4.3.6 Pipeline Analysis 45

4.3.7 Drug Profile 48

4.4 Zolinza (Vorinostat) 49

4.4.1 Indication 49

4.4.2 Mechanism of Action 49

4.4.3 Revenue Forecast 49

4.4.4 Disease Overview 55

4.4.5 Market Potential 55

4.4.6 Pipeline Analysis 61

4.4.7 Drug Profile 63

4.5 Istodax (Romidepsin) 64

4.5.1 Indication 64

4.5.2 Disease Overview 64

4.5.3 Mechanism of Action 65

4.5.4 Market Potential 65

4.5.5 Pipeline Analysis 71

4.5.6 Clinical Studies by Phases 71

4.5.7 Clinical Studies by Indication 72

4.5.8 Drug Profile 73

5 Competitive Landscape 75

5.1 Merck & Co. 75

5.1.1 Company Overview 75

5.1.2 Business Description 75

5.1.3 SWOT 77

5.2 Celgene Corporation 77

5.2.1 Company Overview 77

5.2.2 Business Description 78

5.2.3 SWOT 79

5.3 EISAI 80

5.3.1 Company Overview 80

5.3.2 Business Description 80

5.3.3 SWOT 82

6 Epigenetic Therapeutics: Appendix 83

6.1 Market Definitions 83

6.2 Abbreviations 83

6.3 Research Methodology 84

6.3.1 Coverage 85

6.3.2 Secondary Research 85

6.3.3 Primary Research 85

6.3.4 Forecasts 86

6.3.5 Expert Panel Validation 88

6.4 Contact Us 88

6.5 Disclaimer 88

6.6 Sources 88


1.1 List of Tables

Table 1: List of Approved Epigenetic Drugs, 2010 8

Table 2: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009–2017 9

Table 3: Epigenetic Therapeutics Market, by Geography, Revenue Forecast ($m) 2009–2017 10

Table 4: Epigenetic therapeutics Market, The US, Revenue Forecast ($m) 2009 - 2017 12

Table 5: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009- 2017 13

Table 6: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m), 2009–2017 15

Table 7: Vidaza – Snapshot, 2010 16

Table 8: Vidaza, Global, Revenue Forecast ($m) 2009–2017 17

Table 9: Vidaza, By Geography, Revenue Forecast ($m )2009 - 2017 18

Table 10: Vidaza, The US, Revenue Forecast ($m) 2009–2017 19

Table 11: Vidaza, Europe, Revenue Forecast ($m), 2009–2017 21

Table 12: Vidaza, Japan, Revenue Forecast ($m), 2009–2017 22

Table 13: Vidaza Market Potential, Global, Revenue Forecast ($m) 2012–2017 24

Table 14: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 25

Table 15: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012–2017 26

Table 16: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 27

Table 17: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 28

Table 18: Efficacy of Vidaza in MDS Patients, 2010 32

Table 19: Dacogen – Snapshot, 2010 33

Table 20: Dacogen, Global, Revenue Forecast ($m), 2009–2017 34

Table 21: Dacogen, By Geography, Revenue Forecast ($m), 2009–2017 35

Table 22: Dacogen, The US, Revenue Forecast ($m), 2009–2017 36

Table 23: Dacogen, Europe, Revenue Forecast ($m), 2009– 2017 38

Table 24: Dacogen, Japan, Revenue Forecast ($m), 2009–2017 39

Table 25: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012–2017 40

Table 26: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 41

Table 27: Dacogen, Market Potential, The US, Revenue Forecast ($m), 2012–2017 42

Table 28: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012–2017 43

Table 29: Dacogen, Market Potential, Japan, Revenue Forecast ($m), 2012–2017 44

Table 30: Zolinza Snapshot, 2010 49

Table 31: Zolinza, Global, Revenue Forecast ($m), 2010–2017 50

Table 32: Zolinza, By Geography, Revenue Forecast ($m), 2010–2017 51

Table 33: Zolinza, The US, Revenue Forecast ($m), 2010–2017 52

Table 34: Zolinza, Europe, Revenue Forecast ($m), 2010–2017 53

Table 35: Zolinza, Japan, Revenue Forecast ($m), 2010–2017 54

Table 36: Zolinza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 56

Table 37: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 57

Table 38: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012–2017 58

Table 39: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 59

Table 40: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 60

Table 41: Istodax Snapshot, 2010 64

Table 42: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2010–2017 66

Table 43: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 67

Table 44: Istodax Market Potential, The US, Revenue Forecast ($m), 2010–2017 68

Table 45: Istodax Market Potential, Europe, Revenue Forecast ($m), 2010–2017 69

Table 46: Istodax Market Potential, Japan, Revenue Forecast ($m), 2010–2017 70


1.2 List of Figures

Figure 1: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009–2017 9

Figure 2: Epigenetic therapeutics Market, by Geography, Revenue Forecast ($m) 2009–2017 10

Figure 3: Epigenetic Therapeutics Market, The US, Revenue Forecast ($m) 2009–2017 11

Figure 4: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009–2017 13

Figure 5: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m) 2009–2017 14

Figure 6: Vidaza, Global, Revenue Forecast ($m) 2009–2017 17

Figure 7: Vidaza, By Geography, Revenue Forecast ($m) 2009–2017 18

Figure 8: Vidaza, The US, Revenue Forecast ($m) 2009–2017 19

Figure 9: Vidaza, Europe, Revenue Forecast ($m) 2009–2017 20

Figure 10: Vidaza, Japan, Revenue Forecast ($m), 2009–2017 22

Figure 11: Vidaza Market Potential, Global, Revenue Forecast ($m), 2012–2017 24

Figure 12: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 25

Figure 13: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012–2017 26

Figure 14: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 27

Figure 15: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 28

Figure 16: Vidaza (Azacitidine) – Drug Pipeline, by Phase, 2010 29

Figure 17: Vidaza (Azacitidine) – Drug Pipeline, by Indication, 2009 30

Figure 18: Vidaza (Azacitidine) – Drug Pipeline, by Phase and Indication, 2010 31

Figure 19: Dacogen , Global, Revenue Forecast ($m), 2009–2017 34

Figure 20: Dacogen, By Geography, Revenue Forecast ($m), 2009–2017 35

Figure 21: Dacogen, The US, Revenue Forecast ($m), 2009–2017 36

Figure 22: Dacogen, Europe, Revenue Forecast ($m), 2009–2017 37

Figure 23: Dacogen, Japan, Revenue Forecast ($m), 2009–2017 38

Figure 24: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012–2017 40

Figure 25: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 41

Figure 26: Dacogen Market Potential, The US, Revenue Forecast ($m), 2012–2017 42

Figure 27: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012–2017 43

Figure 28: Dacogen Market Potential, Japan, Revenue Forecast ($m), 2012–2017 44

Figure 29: Dacogen (Decitabine) – Drug Pipeline, by Phase, 2010 45

Figure 30: Dacogen (Decitabine) – Drug Pipeline, by Indication, 2010 46

Figure 31: Dacogen (Decitabine) – Drug Pipeline, by Phase and Indication, 2010 47

Figure 32: Zolinza, Global, Revenue Forecast ($m), 2010–2017 50

Figure 33: Zolinza, Global, Revenue Forecast ($m), 2010–2017 51

Figure 34: Zolinza, The US, Revenue Forecast ($m), 2010–2017 52

Figure 35: Zolinza, Europe, Revenue Forecast ($m), 2010–2017 53

Figure 36: Zolinza, Japan, Revenue Forecast ($m), 2010–2017 54

Figure 37: Zolinza Market Potential, Global, Revenue Forecast ($m), 2012–2017 56

Figure 38: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 57

Figure 39: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012–2017 58

Figure 40: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 59

Figure 41: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 60

Figure 42: Zolinza (vorinostat) – Drug Pipeline, by Phase, 2010 61

Figure 43: Zolinza (vorinostat) – Drug Pipeline, by Indication, 2009 62

Figure 44: Zolinza (vorinostat) – Drug Pipeline, by Phase and Indication, 2010 63

Figure 45: Istodax Market Potential, Global, Revenue Forecast ($m), 2010–2017 66

Figure 46: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 67

Figure 47: Istodax Market Potential, The US, Revenue Forecast ($m), 2010–2017 68

Figure 48: Istodax Market Potential, Europe, Revenue Forecast ($m), 2012–2017 69

Figure 49: Istodax Market Potential, Japan, Revenue Forecast ($m), 2012–2017 70

Figure 50: Istodax (Romidepsin) – Drug Pipeline, by Phase, 2010 71

Figure 51: Istodax (Romidepsin) – Drug Pipeline, by Indication, 2010 72

Figure 52: Istodax (Romidepsin) – Drug Pipeline, by Phase and Indication, 2010 73

Figure 53: SWOT, Merck & Co, 2010 77

Figure 54: SWOT, Celgene Corporation, 2010 79

Figure 55: SWOT, Eisai, 2010 82

Figure 56: GBI Research Market Forecasting Model 87

Companies mentioned

Merck & Co

Celgene Corporation

EISAI

To order this report:

Biotechnology Industry: Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

21%

more press release views with 
Request a Demo